US Pneumococcal Vaccine Market Size study, by Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine) by Product (Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil, Other Products) by End-use (Public Sector, Private Se

US Pneumococcal Vaccine Market Size study, by Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine) by Product (Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil, Other Products) by End-use (Public Sector, Private Sector) Forecasts 2022-2032

US Pneumococcal Vaccine Market is valued approximately USD 3.67 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.90% over the forecast period 2024-2032. The Pneumococcal Vaccine is a vaccine that protects against infection with pneumonia-causing streptococcus bacteria, also known as pneumococcus. This bacterium can cause infections such as meningitis, pneumonia, and bacteremia (a bloodstream infection). The vaccination works by stimulating the immune system to produce antibodies against certain bacterial strains, preventing infection. Also, increasing emphasis on preventive healthcare and the role of vaccines in reducing disease burden and healthcare costs has contributed to a positive outlook for the pneumococcal vaccine market. Healthcare providers and public health agencies are actively promoting pneumococcal vaccination as part of routine preventive care. Thus, this trend is anticipated to support the growth of US Pneumococcal Vaccine Market.

Moreover, growing awareness among healthcare providers and patients about the importance of vaccination in preventing pneumococcal diseases is a significant driver. Public health campaigns, educational programs, and initiatives by healthcare organizations contribute to this awareness. Also, government initiatives such as vaccination programs, recommendations by the Centers for Disease Control and Prevention (CDC), and inclusion of pneumococcal vaccines in routine immunization schedules for children and adults boost market growth. Government-funded vaccination programs, especially for vulnerable populations, further propel market expansion. Additionally, the prevalence of pneumococcal diseases, including pneumonia, meningitis, and bacteremia, remains a concern in the US. The increasing incidence of antibiotic-resistant strains of Streptococcus pneumoniae underscores the need for effective vaccination, thus driving market growth. However, high manufacturing costs are expected to hinder the market growth during the forecast period 2024-2032.


Major market player included in this report are:
Merck & Co., Inc
Pfizer Inc.
Company 3
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Vaccine Type
Pneumococcal Conjugate Vaccine
Pneumococcal Polysaccharide Vaccine

By Product
Prevnar 13
Synflorix
Pneumovax 23
Vaxneuvance
Pneumosil
Other Products

By End-use
Public Sector
Private Sector


Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.